Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension
暂无分享,去创建一个
R. Brook | R. Bard | N. Kaciroti | S. Julius | P. Palatini | J. Bisognano | M. Valentini
[1] G. Molenberghs,et al. Longitudinal data analysis , 2008 .
[2] Donald Hedeker,et al. Longitudinal Data Analysis , 2006 .
[3] T. Ogihara,et al. Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Elevation , 2003, Hypertension.
[4] J. Arch. β3-Adrenoceptor agonists: potential, pitfalls and progress , 2002 .
[5] S. Toubro,et al. Acute effect of L‐796568, a novel β3‐adrenergic receptor agonist, on energy expenditure in obese men , 2002 .
[6] L. Landsberg. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.
[7] S. Toubro,et al. Effects of the two β3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects , 2000, International Journal of Obesity.
[8] R. Miller,et al. Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. , 2000, Journal of medicinal chemistry.
[9] S. Julius,et al. Overweight and hypertension : a 2-way street? , 2000, Hypertension.
[10] P. Arner. Catecholamine-induced lipolysis in obesity , 1999, International Journal of Obesity.
[11] E. Ravussin,et al. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. , 1998, Diabetes.
[12] A. Strosberg,et al. Desensitization of the β-Adrenergic Response in Human Brown Adipocytes. , 1998, Endocrinology.
[13] S. Toubro,et al. Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[14] C. Stein,et al. Forearm beta adrenergic receptor-mediated vasodilation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension. , 1995, The Journal of clinical investigation.
[15] S. Kjeldsen,et al. Sympathetic Nervous System Involvement in Essential Hypertension: Increased Platelet Noradrenaline Coincides with Decreased β-Adrenoreceptor Responsiveness , 1994 .
[16] A. Strosberg,et al. The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. , 1993, Molecular pharmacology.
[17] M. Dutia,et al. Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent. , 1992, Journal of medicinal chemistry.
[18] R. Schwartz,et al. Reduced metabolic rate during β-adrenergic blockade in humans☆ , 1991 .
[19] N. Schork,et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan , 1991, Journal of hypertension.
[20] R. Feldman. Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. , 1990, The Journal of clinical investigation.
[21] I. Macdonald,et al. Catecholamines and the control of metabolism in man. , 1985, Clinical science.
[22] D. Robbins,et al. Effects of Chronic β-Receptor Stimulation on Sympathetic Nervous System Activity, Energy Expenditure, and Thyroid Hormones , 1984 .
[23] O. Bertel,et al. Decreased Beta‐Adrenoreceptor Responsiveness as Related to Age, Blood Pressure, and Plasma Catecholamines in Patients with Essential Hypertension , 1980, Hypertension.
[24] P. Kissinger,et al. Determination of catecholamines in urine by reverse-phase liquid chromatography with electrochemical detection. , 1977, Analytical chemistry.
[25] S. Julius,et al. Mild high-renin essential hypertension. Neurogenic human hypertension? , 1977, The New England journal of medicine.
[26] S. Julius,et al. Altered Cardiac Responsiveness and Regulation in the Normal Cardiac Output Type of Borderline Hypertension , 1975, Circulation research.
[27] F. Epstein,et al. Overweight and Hypertension: A Review , 1969, Circulation.
[28] W. Kannel,et al. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. , 1967, Annals of internal medicine.
[29] J. B. Weir. New methods for calculating metabolic rate with special reference to protein metabolism , 1949, The Journal of physiology.
[30] Beretta-Piccoli,et al. Plasma Catecholamines and Essential Hypertension An Analytical Review , 2005 .
[31] A. Strosberg,et al. Desensitization of the beta-adrenergic response in human brown adipocytes. , 1998, Endocrinology.
[32] T. Ogihara,et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. , 1997, American journal of hypertension.
[33] A. Hill,et al. Serotoninergic modulation of the pattern of eating and the profile of hunger-satiety in humans. , 1987, International journal of obesity.
[34] D. Robbins,et al. Effects of chronic beta-receptor stimulation on sympathetic nervous system activity, energy expenditure, and thyroid hormones. , 1984, The Journal of clinical endocrinology and metabolism.